Home > Clinical Trials
Check All Search

Saved trials

NOT_YET_RECRUITING
NCT06711978
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
66 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
CIPN


CIPN - Chemotherapy-Induced Peripheral Neuropathy


CIPN in Adjuvant Breast Cancer Patients


Duloxetine


Mirogabalin
RECRUITING
NCT04635111
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
30 Enrollment(s)
8 Study location(s)
OBSERVATIONAL (None)
Hepatotoxicity


Tenosynovial Giant Cell Tumor
NOT_YET_RECRUITING
NCT06608472
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
292 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Essential Arterial Hypertension
RECRUITING
NCT06102824
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
252 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-negative Breast Cancer


Advanced Breast Cancer
RECRUITING
NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
358 Enrollment(s)
11 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Tumor


Metastatic Solid Tumor


Soft Tissue Sarcoma (STS)


Platinum-resistant Ovarian Cancer (PROC)


Hepatocellular Carcinoma (HCC)


Colorectal Cancer (CRC)


HER2 Negative Breast Cancer


Cutaneous Melanoma


Renal Cell Carcinoma (RCC)
COMPLETED
NCT04989816
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
95 Enrollment(s)
24 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RECRUITING
NCT05034887
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
64 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma
COMPLETED
NCT04744831
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
122 Enrollment(s)
63 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Colorectal Cancer